What is the most recent FDA action on file for Exela Pharma Sciences LLC?

November 15, 2024. Argus HQ ingests new FDA enforcement records daily.

Is this FDA enforcement data for Exela Pharma Sciences LLC official?

Every record links directly to its primary FDA.gov source. Argus HQ aggregates and structures public FDA data; the verbatim FDA record is always the source of truth.

How many FDA actions has Exela Pharma Sciences LLC had?

Argus HQ has recorded 1 FDA events for Exela Pharma Sciences LLC: 0 warning letters, 0 recalls, 0 approvals, and 1 Form 483 inspection observations. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

What is the most recent FDA action against Exela Pharma Sciences LLC?

The most recent FDA event Argus HQ has on file for Exela Pharma Sciences LLC is dated 2024-11-15, with a severity rating of "high" in Argus HQ's classification. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

FDA Actions Against Exela Pharma Sciences LLC

Here's the summary: Argus HQ has recorded 1 FDA events for Exela Pharma Sciences LLC: 0 warning letters, 0 recalls, 0 approvals, and 1 inspection 483 observations. These events span from 2024-11-15 to 2024-11-15. The most severe rating Argus HQ has assigned across this history is "high". Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed.

FDA action counts

Total FDA actions	1
Warning letters	0
Recalls	0
Approval records	0
Form 483 inspection citations	1
Most recent action	November 15, 2024

Enforcement history

On 2024-11-15, Argus HQ recorded an FDA Form 483 inspection citation for Exela Pharma Sciences LLC, rated "high" severity in Argus HQ's classification: Exela Pharma Sciences LLC -- FDA 483: 15 observations (2024-11-15). Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed.

Risk pattern analysis

Argus HQ analysis — not an FDA finding

This section is Argus HQ analysis, not an FDA finding. Exela Pharma Sciences LLC has 1 FDA event on file. A pattern across multiple FDA touchpoints does not by itself establish that any specific product currently poses a risk; it reflects only the frequency of FDA engagement with this company as recorded in Argus HQ's database. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ does not independently verify FDA's underlying findings; this page summarizes what FDA has published and links back to the original FDA source for each event. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

Frequently asked questions

What is the most recent FDA action on file for Exela Pharma Sciences LLC?: November 15, 2024. Argus HQ ingests new FDA enforcement records daily.
Is this FDA enforcement data for Exela Pharma Sciences LLC official?: Every record links directly to its primary FDA.gov source. Argus HQ aggregates and structures public FDA data; the verbatim FDA record is always the source of truth.
How many FDA actions has Exela Pharma Sciences LLC had?: Argus HQ has recorded 1 FDA events for Exela Pharma Sciences LLC: 0 warning letters, 0 recalls, 0 approvals, and 1 Form 483 inspection observations. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.
What is the most recent FDA action against Exela Pharma Sciences LLC?: The most recent FDA event Argus HQ has on file for Exela Pharma Sciences LLC is dated 2024-11-15, with a severity rating of "high" in Argus HQ's classification. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

Every FDA action tied to this company, the week it happens.

Free weekly briefing. Real-time alerts on paid plans.

Exela Pharma Sciences LLC -- FDA 483: 15 observations (2024-11-15) →

Compare with

Two different companies merged onto this page by mistake? Or a name variant missing? Tell us — corrections@argushq.ai

Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder

Cite this record

Reusing this data in reporting or research? Here’s a ready-made citation.

APA

Argus HQ Research (2024). FDA Actions Against Exela Pharma Sciences LLC. Digital Empire LLC. Retrieved from https://argushq.ai/company/exela-pharma-sciences-llc

MLA

"FDA Actions Against Exela Pharma Sciences LLC." Argus HQ Research, Digital Empire LLC, 2024, argushq.ai/company/exela-pharma-sciences-llc.

Chicago

Argus HQ Research. "FDA Actions Against Exela Pharma Sciences LLC." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/company/exela-pharma-sciences-llc.

BibTeX

@misc{argushq_argushq_ai_company_exela_pharma_sciences_llc_2024,
  title = {FDA Actions Against Exela Pharma Sciences LLC},
  author = {{Argus HQ Research}},
  year = {2024},
  publisher = {Digital Empire LLC},
  url = {https://argushq.ai/company/exela-pharma-sciences-llc},
  note = {Accessed: July 13, 2026}
}

Source: FDA.gov (aggregated across Warning Letters, Recalls, Approvals, Form 483s) ↗